To determine which patient and treatment-related factors are associated with increased American Urological Association symptom score (AUASS) in men who presented with minimal symptoms before treatment for prostate cancer by permanent seed implantation.
Introduction
Radiation therapy (RT) is an accepted treatment method for localised prostate cancer. There are several different methods of delivering radiation including external beam RT (EBRT) and brachytherapy (BT). EBRT is delivered as a fractional dose, typically as 1.8-2.0 Gy over 7-9 weeks. BT is administered as continuous irradiation by insertion of radioactive sources directly into the target tissue. These sources can be temporary, such as 192 Ir or permanent, such as 125 I. 192 Ir is usually given as a high-dose rate, where the radioactive source is left in the tissue for a brief period of time. In contrast, 125 I is a sealed source that delivers a low radiation dose continuously for as long as 10 months (five half-lives). One of the advantages of BT is that a relatively higher dose can be delivered to the prostate compared to EBRT. However, whilst local tumour control can be enhanced, it may come at a price of increased long-term morbidity, especially in urinary function.
Morbidity from RT is related to several factors: the type and dose of radiation, the tissue receiving the radiation, the recovery potential of the irradiated tissue, and the time frame at which side-effects are determined. Whole gland therapy, regardless of the type, radical prostatectomy, EBRT, cryoablation or BT, is associated with substantial urinary morbidity. The early side-effects for prostatectomy, incontinence, and for BT, obstruction from gland swelling and marked dysuria from acute radiation prostatitis, have been well characterised. Incontinence improves within a year after prostate removal and symptom scores return to baseline within 2 years after BT [1, 2] . However, urinary symptoms are known to further deteriorate over time after EBRT and BT [3, 4] . Most studies report symptom changes for the entire treated population without differentiating potential harm to those who present without initial urinary bother.
The implant programme at our institution began in 1990, with the intention of delivering a higher radiation dose than what was conventionally achieved at that time. We reported the advantages of higher doses 15 years ago, demonstrating better local control (by biopsy) and lower systemic relapse [5] . In 2006, we introduced the concept of the biological equivalent dose (BED), allowing determination of a common dose that would account for radiation delivered by both the implant and EBRT [6] . In the present study, we define the long-term risk for men, who presented with mild urinary symptoms (AUA symptom score [AUASS] of 0-7) of developing worsening urinary complaints when treated with prostate BT.
Patients and Methods
In all, 1 842 men with T1-T3 prostate cancer were treated by BT and followed for a minimum of 5 years (mean 9.4, range [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and completed a pre-treatment AUASS. Of these, 1110 (60.3%) had minimal urinary symptoms (AUASS 0-7 Before implantation and at each follow-up visit patients were asked to complete the 35-point AUASS and 6-point quality of life (QOL) bother score. In all, 1842 men had completed both the initial pre-implantation and last AUASS assessment. A total of 1110 (60.3%) men had minimal initial urinary symptoms (AUASS of 0-7), 641 (34.8%) moderate symptoms (AUASS of [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and 91 (4.9%) severe symptoms (AUASS of [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . The QOL score was 0-2 in 1420 (77.1%) men, 3 in 254 (13.8%), and 4-6 in 168 (9.1%). The median (range) prostate volume was 37 (2.4-188.1) mL. Data were prospectively collected on comorbidities and included: smoking, hypertension (HTN), asthma, emphysema, alcohol abuse, other cancers, and whether a pre-or post-implantation TURP was performed.
The initial AUASS was compared to last using a two-tailed Student's t-test. Bootstrapping was applied to 1000 samples. Associations for age, prostate volume, NHT use, BED, EBRT boost, and comorbidities, were compared by ANOVA and chisquared (Pearson). Freedom from initial minimal symptoms (AUASS of 0-7) increasing to moderate or severe symptoms (AUASS 8-19 and 20-35, respectively) were determined by Kaplan-Meier method with comparisons by log-rank and Cox hazard rates (HRs). Univariate findings with P ≤ 0.1 were placed in the multivariate model (Cox). Statistics were computed using the Statistical Package for the Social Sciences (SPSS â ) version 20 (SPSS Inc., IBM Corp., Armonk, NY, USA).
Results
The median (range) age of the patients was 66 (39-85) years and the PSA level was 6.7 (0.3-300) ng/mL. For all 1842 men, the AUASS increased from a mean (SD) of 7.4 (5.9)-9.2 (7.0) (P < 0.001, bootstrap P = 0.001) and the QOL bother score from 1.59 (1.39)-1.98 (1.48) (P < 0.001, bootstrap P = 0.001). The median (IQR) increase was 1.0 (À2 to +5) points. The changes from pre-treatment to last score for the minimal, moderate and severe symptom groups were: 3.6-7.3 (P < 0.001), 11.6-11.3 (P = 0.426), and 24.1-16.9 (P < 0.001). Men with moderate-to-severe symptoms were older, had larger prostate volumes, and were more likely to receive NHT (Table 1) . TURP was performed in 91 (4.9%) men before implantation for BPH unrelated to their prostate cancer and in 75 (4.1%) after treatment because of obstructive symptoms. There was no association between urinary symptoms and a prior TURP, whilst men with more severe urinary symptoms were more likely to have a TURP after treatment. For the 1110 men with minimal symptoms, the 10-and 15-year estimates for freedom from worse symptoms (from mild to moderate and severe) were 72.9% and 39.1%, respectively (Fig. 1) . The mean time to worsening symptoms was 13.0 Table 2 . The use of EBRT boost significantly worsened urinary symptoms (Fig. 2) . Men who received EBRT had substantially higher radiation doses: 205.8 vs 190.5 Gy 2 compared to those without a boost (P < 0.001). In men treated without EBRT, higher radiation dose also impacted urinary symptoms. The 10-and 15-year freedom from worsening symptoms was 79.9% and 54.3% for those with a BED <200 Gy 2 (n = 389) vs 73.7% and 36.3% for a BED ≥200 Gy 2 (n = 293, P = 0.003). TURPs performed before (P = 0.975) and after (P = 0.109) implantation were not associated with worsening urinary symptoms. While there was also no association with a pre-treatment TURP and worse QOL, a post-treatment TURP was associated with increased bother (P = 0.05, Fig. 3 ). Cox HRs for worsening symptoms were for EBRT boost 1.45 (P = 0.004), a BED ≥200 Gy 2 1.25 (P = 0.024), HTN 1.37 (P = 0.006), and alcohol use 1.46 (P = 0.001) ( Table 3 ). In the men treated by BT alone (no EBRT) significant Cox HRs were for a BED of ≥200 Gy 2 1.40 (95% CI 1.1-1.8, P = 0.013) and alcohol use 1.55 (95% CI 1.2-2.1, P = 0.003).
Discussion
Radiation therapy dose escalation is associated with improved local control, freedom from biochemical failure and causespecific survival [7] [8] [9] . How much escalation is needed has never been fully defined. Dose escalation is greatest when BT is combined with EBRT. A number of non-randomised studies suggest this may be the best approach for men with high-risk prostate cancer [10, 11] . However, higher doses may be implicated in long-term urinary morbidity.
The occurrence of temporary urinary symptoms after BT has been well documented. Keyes et al. [12] reported on 712 implantation-only patients followed for a median of 57 months. AUASS returned to baseline at a median of 12.6 months. They also noted that higher RT dose was associated with more Radiation Therapy Oncology Group (RTOG) Grade 2 urinary toxicity. Merrick et al. [13] mailed the AUASS to 225 BT patients with a median follow-up of 64 months, which they compared to a control group. The only factor associated with diminished QOL was tobacco use. In the present study, we also found smoking resulted in more men developing moderate or severe symptoms. Eriguchi et al. [14] applied the BED calculations in 1313 men treated with BT with or without EBRT. They found increased AUASS of 6.2 points at 3 months, which decreased to 0.6 points by 5 years. Greater Grade 2 genitourinary toxicity was associated with a larger prostate and use of NHT. There was no association with higher BED. Crook analysed 484 men treated by 125 I BT and followed for a median of 41 months. In all, 14% of the men had NHT to reduce prostate size [15] . An increase of >5 points above baseline with a total score >15 was seen in 23%. The only factor in the multivariable model predictive of a prolonged elevated AUASS was age.
Several studies have evaluated whether large prostate size adversely affects long-term urinary symptoms. When stratified by size, Niehaus et al. [16] found an increase in temporary urinary catheter requirement with larger glands but eventual normalisation of AUASS for all groups. Pham et al. [17] examined toxicity in 2076 men who received BT and subdivided them into those with prostate glands > or <60 mL. With a median follow-up of 55 months, those with larger glands had more Grade 2 genitourinary toxicity (7.2% vs 3.2%, P < 0.001). Stone et al. [18] evaluated urinary symptoms in 1 932 men at 10 years after BT. The mean initial symptom score was the same, at 7.4, as the present study. With a mean follow-up of 6.8 years, the mean increase in AUASS was +1.4, which was slightly less than the mean 1.8 (median 1.0) increase reported in the present study. Within the first 4 years of implantation, RT dose, NHT, prostate size, and the use of EBRT were associated with higher scores. At 10 years these associations were no longer significant. That study, like most others, evaluated AUASS changes across a cohort that included men with low and high initial scores. When averaging scores, patients with high 11.4-13.6) for implantation followed by TURP (P = 0.052). In the present study, we sought to characterise the long-term harm to men receiving BT in those presenting with minimal urinary symptoms. In the 1110 men with an AUASS of ≤7 before BT the likelihood of remaining with minimal symptoms after treatment was 72.9% at 10 years and 39.1% at 15 years. In the univariate analyses, higher RT doses, the use of EBRT boost, HTN, alcohol use, and smoking were associated with worse symptoms. In the multivariate EBRT, RT dose, HTN and alcohol use remained significant. In a sub-analysis of implantation-only patients (no EBRT) an RT dose of >200 Gy 2 was significant. These data suggest that RT dose may need to be limited to 200 Gy 2 to prevent long-term urinary morbidity. The upper dose for successful eradication of all local tumour burden has not been fully elucidated but data from several studies suggest it may be 200 Gy [19] [20] [21] .
While the data from the present study may help inform men about their risk of long-term urinary symptoms after BT, it is a single institution's experience, which may limit its applicability. While AUASSs were collected prospectively, there was no control population for comparison. Given the long follow-up, it was not possible to separate a 'natural' decline in urinary symptoms associated with ageing. Smith et al. [22] analysed 106 435 men aged ≥45 years, living in New South Wales, Australia for association of urinary symptoms and age, co-morbidities, and life-style factors. Overall, 18.3% reported moderate, and 3.6% severe, LUTS. Severe LUTS were more common amongst men reporting previous prostate cancer (7.6%), total prostatectomy (4.9%) or having part of the prostate removed (8.2%). After excluding men with prostate cancer or prostate surgery, the prevalence of moderate-severe LUTS in the cohort (n = 95 089) ranged from 10.6% to 35.4% for ages 45-49 to ≥80 years; the agerelated increase was steeper for storage than voiding symptoms. While many men in that observation study probably had symptoms related to an enlarging prostate, patients with prostate cancer treated by BT experience a 50% decline in prostate size over time [23] . Thus, it is more likely that the worsening urine symptoms reported in the present study are secondary to the higher RT doses and not BPH. Similar to the present study, Smith et al. [22] also reported that current smokers had a greater risk of worse urinary symptoms (odds ratio 1.64, 95% CI 1.43-1.88). Marshall et al. [24] assessed men aged ≥65 years with the AUASS at baseline and then every 2 years thereafter. In all, 20% progressed and were more likely to have mobility limitations, poor mental health, body mass index ≥25.0 kg/m 2 , HTN, and back pain. It is likely some of these factors (especially smoking, HTN, and alcohol use) affected urinary symptoms after BT, but it is also likely that higher RT doses (by addition of EBRT or a BED of >200 Gy 2 ) were also a significant contributing factor.
Conclusions
While an analysis of mean changes in the AUASS 10-15 years after prostate BT does not suggest patient harm, the number of men who change from minimal to moderate and severe urinary symptoms is substantial. Treatment-related factors, such as the addition of EBRT and delivering RT doses >200 Gy 2 contribute to more urinary symptoms. HTN and alcohol use also increase urinary complaints long after treatment. This information should guide physicians when they counsel patients about treatment choices for localised prostate cancer.
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